EP 3334419 A1 20180620 - SOLID PHARMACEUTICAL COMPOSITION OF ABACAVIR, LAMIVUDINE, AND EFAVIRENZ
Title (en)
SOLID PHARMACEUTICAL COMPOSITION OF ABACAVIR, LAMIVUDINE, AND EFAVIRENZ
Title (de)
FESTE PHARMAZEUTISCHE ZUSAMMENSETZUNG VON ABACAVIR, LAMIVUDIN UND EFAVIRENZ
Title (fr)
COMPOSITION PHARMACEUTIQUE SOLIDE D'ABACAVIR, DE LAMIVUDINE ET D'ÉFAVIRENZ
Publication
Application
Priority
- EP 15181145 A 20150814
- EP 2016069261 W 20160812
Abstract (en)
[origin: WO2017029226A1] The present invention describes a fixed dose oral formulation of a triple HIV antiviral combination of abacavir (notably abacavir sulphate), lamivudine and efavirenz, useful in the treatment of HIV infections. The described formulations combine a number of valuable use attributes, including reduction of mouth burning effect caused by efavirenz as well as for providing of palatable formulations for high drug loaded system that is important for a triple fixed dose combination, without however to the detriment of dissolution properties for each active ingredient.
IPC 8 full level
A61K 9/20 (2006.01); A61K 9/28 (2006.01); A61K 31/52 (2006.01); A61K 31/536 (2006.01); A61K 31/7068 (2006.01)
CPC (source: EP)
A61K 9/2054 (2013.01); A61K 9/284 (2013.01); A61K 31/513 (2013.01); A61K 31/52 (2013.01); A61K 31/536 (2013.01)
Citation (search report)
See references of WO 2017029226A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2017029226 A1 20170223; EP 3334419 A1 20180620; WO 2017029225 A1 20170223
DOCDB simple family (application)
EP 2016069261 W 20160812; EP 16750854 A 20160812; EP 2016069260 W 20160812